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Abstract. The study included 135 breast cancer patients (70 patients with locally recurrent breast cancer and 65 patients 
with locally advanced breast cancer with unfavorable prognostic factors) who received the neutron therapy alone or in 
combination with the photon therapy. The neutron therapy was shown to be effective in multimodality treatment of 
patients with locally advanced and locally recurrent breast cancer. The 8-year survival rate in patients without repeated 
breast cancer recurrence was 87.6 ± 8.7% after the neutron and neutron-photon therapy and 54.3 ± 9.2% after the electron 
beam therapy. 
INTRODUCTION
A long-term experience in treating breast cancer has shown that the conventional postoperative radiation therapy 
including photon and electron therapy reduces the risk of breast cancer recurrence from 38% to 5% [1, 2]. The basic 
effect of ionizing radiation is to destroy the ability of cells to divide, by damaging their DNA strands. If a tumor cell 
is damaged by photon and electron radiation, it has a good chance to repair itself and continue to grow. By using 
neutron radiation therapy, the chance for a damaged tumor cell to repair itself is very small. Unlike photons, 
neutrons do not depend on the presence of oxygen to kill the cancer cells. In addition, the biological effectiveness of 
neutrons is not affected by the time or stage in the life cycle of cancer cells [3]. The application of 6.3 MeV fast 
neutrons in treatment of malignant neoplasms is one of the possible ways to overcome radioresistance [4–6]. 
The purpose of the study was to evaluate the effectiveness of 6.3 MeV fast neutrons in the treatment of patients 
with locally advanced and locally recurrent breast cancer. 
MATERIALS AND METHODS
The therapeutic neutron bunch is received on a cyclotron U-120 when bombing a beryllium target by deuterons 
with energy of 13.5 MeV. The average energy of fast neutrons bunch is ~6.3 MeV [7–11]. 
A total of 227 breast cancer patients were included into the study. Eligibility criteria were as follows: locally 
advanced breast cancer recurrence; local recurrence after multimodality treatment of primary breast cancer with 
preoperative external beam radiotherapy delivered to the whole breast; radioresistant local recurrence of breast 
cancer after previously irradiated recurrent tumor; continuous tumor growth after multimodality treatment of 
infiltrative ductal breast carcinoma. 
All patients were divided into 2 groups. Group I consisted of 114 patients with locally recurrent breast cancer 
(T2-4N0-2M0). This group was subdivided into the study group (70 patients) and the control group (44 patients). The 
study group patients received neutron therapy given twice a week with a 48–72 hour-interval using the U-120 
cyclotron.  
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FIGURE 1. Therapeuticneutron beam scheme and the position ofthe patient duringirradiation session Radiation is carried  
out with the horizontal fixed bunch, at 110 cm distance from a target: 1, 2—ionconductor, 3—beryllium target camera,  
4—berylliumtarget, 5—iron shielding, 6—polyethylene shielding, 7—removable plastic collimator, 8–10—parts  
of thetreatment chair, 11—laser therapy device 
 
The radiation field size was 96?248 cm2 depending on the extent of local recurrence. Fast neutron beam was 
directed perpendicular to the chest wall at a source-to-skin surface distance of 110 cm. Single radiation dose was 
1.6–2.0 Gy (2.91–2.79 RBE), the skin dose was 2.0–2.2 Gy (2.79–2.73 RBE) [12–14]. Twenty-eight (37%) of the 
70 patients with locally advanced breast cancer recurrences received the neutron therapy alone at a total dose of 30–
40 isoGy and 44 (63%) patients received the combination of the neutron and photon therapy at a total dose of 50–
60 isoGy [15]. 
The control group included 44 patients with local breast cancer recurrence who received the electron beam 
therapy at a total dose of 60 Gy. The mean follow-up time for 114 patients of both the study and the control groups 
was 7 ± 0.5 years. 
Group II comprised 113 patients with stage T2-4N0-3M0-1 locally advanced breast cancer with unfavorable 
prognostic factors, such as invasive ductal carcinoma, multicentric tumor growth and angiolymphaticinvansion. 
They underwent multimodality treatment including neoadjuvant chemotherapy (NACT) and adjuvant chemotherapy 
(ACT) according to CMF, CAF/FAC schemes, antiestrogen therapy (if indicated), radical mastectomy (RM) and 
radiotherapy. 
The study group consisted of 65 breast cancer patients (T2-4N0-3M0-1), who from 2007 to 2014 received 3–
4 sessions of the neutron therapy alone. The radiation field size was 96?200 cm2. A single radiation dose was 1.4–
1.76 Gy with skin dose of 1.75–2.2 Gy. The total tumor dose was 16.7–29.9 isoGy with skin dose of 25.6–41 isoGy 
[16]. The control group comprised 48 breast cancer patients (T2-4N0-3M0) who, from 2004 to 2006, received electron 
beam therapy in a single dose of 3.0 Gy to the total dose of 38–44 isoGy delivered to the region of the anterior chest 
wall.  
All 113 patients received the postoperative external beam radiotherapy at a total dose of 40–44 Gy delivered to 
the regional lymph nodes. 
RESULTS 
The neutron therapy was well tolerated and 1–2 grade radiation skin reactions were the most common. 
In the group of patients with local breast cancer recurrence, 3 (4%) out of the 70 patients had re-recurrences after 
previous neutron and neutron-photon therapy. In the control group after the electron beam therapy, repeated local 
recurrences of breast cancer were observed in 17 (39%) of 44 patients. The 8-year survival rate in patients without 
repeated breast cancer recurrence was 87.6 ± 8.7% after the neutron and neutron-photon therapy and 54.3 ± 9.2% 
after the electron beam therapy (p = 0.0001). 
Late radiation-induced damages to normal tissues. Twenty (16%) out of 70 patients with local breast cancer 
recurrence after the neutron and neutron-photon therapy had late local radiation-induced skin and subcutaneous 
tissue injuries. When planning TDF, the analysis of the incidence of radiation-induced pulmonary fibrosis depending 
on the isoeffective doses was carried out.  
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FIGURE 2. Appearance of patient with local breast cancer recurrence before (a) and after (b) neutron therapy  
(complete regression) 
 
After the neutron therapy, 3 (11.5%) out of 26 patients with recurrent breast cancer developed grade 1 radiation 
pulmonary fibrosis (RTOG/EORTC). Factors: strictly perpendicular direction of the cyclotron collimator to the 
chest wall, more than 148 cm² irradiation area, 1.76 Gy single dose and more than 5 treatment sessions. Photon 
equivalent dose (PED) to the lung was 33 Gy. In the case of mixed neutron-photon radiation therapy, 11 (25%) out 
of the 44 patients with local recurrence developed radiation-induced pulmonary fibrosis (grade 1 pulmonary fibrosis 
in 4 (9%) patients, grade 2 in 6 (14%) patients and grade 3 in 1 (2%) patients). 
In Group II patients with unfavorable prognostic factors, moist desquamation after the neutron therapy was 
observed only in 3 (5%) out of the 65 patients, requiring administration of magneto-laser therapy. Radiation-induced 
pulmonary fibrosis was diagnosed in only 4 (6%) out of the 65 patients with breast cancer. Radiation-induced 
damages to lung tissue were treated with antibacterial and hormonal agents with a positive effect. The 7-year 
recurrence-free survival rate in the study group of the patients receiving neutron therapy to the region of the anterior 
chest wall was 93.4 ± 4.6%. In the control group of the patients who received electron beam therapy, the 
corresponding value was 77.5 ± 7.9% (p = 0.04). The overall 7-year survival rate was 85.4 ± 5.3% in the study 
group and 43.3 ± 9.2% in the control group (p = 0.0002). 
A significant statistical difference between the groups was not found; however, the following facts should be 
given in favor of the neutron therapy, namely: 1) combination of several unfavorable prognostic factors in breast 
cancer patients in the study group, 2) development of radioresistant forms of local recurrences after electron beam 
therapy in the control group. 
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FIGURE 3. The 7-year recurrence-free survival rate in the study and control groups 
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CONCLUSIONS 
The neutron therapy was shown to be effective in multimodality treatment of patients with locally advanced 
breast cancer, and it is often the only treatment to prolong the life of patients with locally advanced breast cancer 
recurrence. 
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